- Home
- OKYO vs GANX Comparison
OKYO vs GANX Comparison
Compare OKYO & GANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | OKYO | GANX |
|---|---|---|
| Founded | 2007 | 2017 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 85.3M | 100.4M |
| IPO Year | 2021 | 2021 |
Fundamental Metrics
Financial Performance| Metric | OKYO | GANX |
|---|---|---|
| Price | $1.72 | $2.95 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 6 |
| Target Price | $6.33 | ★ $8.00 |
| AVG Volume (30 Days) | 361.7K | ★ 616.6K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 47.95 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $55,180.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.03 | $1.41 |
| 52 Week High | $3.35 | $4.34 |
Technical Indicators
Market Signals| Indicator | OKYO | GANX |
|---|---|---|
| Relative Strength Index (RSI) | 43.36 | 66.31 |
| Support Level | $1.52 | $1.60 |
| Resistance Level | $2.25 | $3.06 |
| Average True Range (ATR) | 0.13 | 0.24 |
| MACD | 0.01 | 0.10 |
| Stochastic Oscillator | 57.58 | 91.06 |
Price Performance
Historical ComparisonAbout OKYO OKYO Pharma Limited
OKYO Pharma Ltd is a biopharmaceutical company. The company is developing therapeutics to improve the lives of patients with inflammatory eye diseases and chronic pain. It offers solutions for various diseases such as Dry Eye Disease, Non-infectious Anterior Uveitis, Allergenic Conjunctivitis, Chronic Pain, and Ocular Pain.
About GANX Gain Therapeutics Inc.
Gain Therapeutics Inc is a biotechnology company developing novel small molecule therapeutics to treat diseases across several therapeutic areas, including, lysosomal storage disorders, central nervous system disorders, metabolic disorders, and oncology. The company's clinical-stage product candidate, GT-02287, is being developed for the treatment of GBA1 Parkinson's disease. The company uses its computational target and drug discovery platform, Magellan, to discover novel allosteric binding sites on proteins implicated in disease and to identify proprietary small molecules that bind these sites to modulate protein function and treat the underlying cause of the disease. Geographically, the company operates in Switzerland, Spain, the United States, and Australia.